Trial Profile
A study investigating pharmacokinetics, safety and efficacy of Sunitinib in patients with advanced renal cell carcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 28 Dec 2015 New trial record